The Kidney Cancer Association is proud to offer the following free CME sessions to healthcare professionals interested in advancing their clinical knowledge in kidney cancer.
Virtual Tumor Board: Contemporary Topics in Renal Cell Carcinoma
This interactive tumor board reviews challenging cases which highlight clinical characteristics in locally advanced metastatic clear cell RCC (ccRCC) that help direct systemic therapy. This tumor board is presented by Drs. Christopher Wood, Robert Figlin, Brad Leibovich, Sumanta (Monty) Pal and Brian Rini.
This lecture identifies targetable pathways that drive specific RCC histologies and distinguish which renal cell carcinoma histologies can respond to tyrosine kinase inhibitors, immune checkpoint blockade, or cytotoxic chemotherapy. This activity is presented by Pavlos Msaouel, MD, PhD. [EXPIRED]
This lecture focuses on recent cytoreductive nephrectomy (CN) trials and reviews which patients with primary metastatic clear-cell renal cell carcinoma (ccRCC) may benefit from CN. This activity is presented by Axel Bex, MD, PhD. [EXPIRED]
This lecture explores options for patients with metastatic renal cell carcinoma (RCC) following treatment with VEGF-TKI-targeted agents and ex options for patients with metastatic RCC following treatment with immune checkpoint inhibitors (ICIs), including other ICIs and agents with novel targets. This activity is presented by Toni Choueiri, MD. [EXPIRED]
This lecture reviews evidence of salvage therapy for mRCC, timing for palliative care interventions and the goal of palliative care. This activity is presented by Sumanta K. Pal, MD. [EXPIRES 11/3/21]
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the Kidney Cancer Association. The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
TUMOR BOARD: The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
VIRTUAL LECTURES: The France Foundation designates these enduring activities for a maximum of 0.5 AMA PRA Category 1 Credit(s)™each. Physicians should claim only the credit commensurate with the extent of their participation in the activities.
TUMOR BOARD: This course has been designated 0.5 credit(s) of education in medical ethics and/or professional responsibility.
VIRTUAL LECTURES: These courses have been designated 0.5 credit(s) each of education in medical ethics and/or professional responsibility.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.